|
|
Vaccine Detail
|
Mixed bacterial vaccine |
| Vaccine Information |
- Vaccine Name: Mixed bacterial vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Inactivated or "killed" vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Immunization Route: intralesionally or subcutaneously
- Description: This is a cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). (NCIT_C74063) The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination. (NCT00623831)
|
| Host Response |
|
|
| References |
NCIT_C74063: Mixed Bacteria Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063]
NCT00623831: A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen [https://clinicaltrials.gov/study/NCT00623831]
|
|
